Documents
-
- Download
- Title Pages_Contents
-
open access
-
- Download
- Chapter 1
-
open access
- Full text at publishers site
-
- Download
- Chapter 2
-
open access
- Full text at publishers site
-
- Download
- Chapter 3
-
open access
- Full text at publishers site
-
- Download
- Chapter 4
-
open access
- Full text at publishers site
-
- Download
- Chapter 5
-
open access
- Full text at publishers site
-
- Download
- Chapter 6
-
open access
- Full text at publishers site
-
- Download
- Summary in Dutch
-
open access
-
- Download
- Propositions
-
open access
In Collections
This item can be found in the following collections:
Developing an antisense oligonucleotide treatment for Spinocerebellar Ataxia Type 3
Spinocerebellar ataxia type 3 (SCA3) is a hereditary neurodegenerative disorder caused by a CAG triplet repeat expansion in the ATXN3 gene. This expanded CAG repeat is translated into a toxic polyglutamine repeat in the ataxin-3 protein. Over time, expression of the expanded ataxin-3 protein leads to neurodegeneration of particularly the cerebellum and brainstem in SCA3 patients. Currently, there is no treatment available for SCA3. In light of its monogenetic nature, SCA3 is a good candidate for genetic therapies. In the research described in this thesis, antisense oligonucleotides were tested as a potential therapy for SCA3. The antisense oligonucleotides were used to induce exon skipping at RNA level in order to remove toxic protein regions (proteolytic cleavage sites or the polyglutamine repeat) from the ataxin-3 protein. In addition to the therapeutic research, transcriptomic analysis of brain material from transgenic SCA3...
Show moreSpinocerebellar ataxia type 3 (SCA3) is a hereditary neurodegenerative disorder caused by a CAG triplet repeat expansion in the ATXN3 gene. This expanded CAG repeat is translated into a toxic polyglutamine repeat in the ataxin-3 protein. Over time, expression of the expanded ataxin-3 protein leads to neurodegeneration of particularly the cerebellum and brainstem in SCA3 patients. Currently, there is no treatment available for SCA3. In light of its monogenetic nature, SCA3 is a good candidate for genetic therapies. In the research described in this thesis, antisense oligonucleotides were tested as a potential therapy for SCA3. The antisense oligonucleotides were used to induce exon skipping at RNA level in order to remove toxic protein regions (proteolytic cleavage sites or the polyglutamine repeat) from the ataxin-3 protein. In addition to the therapeutic research, transcriptomic analysis of brain material from transgenic SCA3 mice was performed to further elucidate potential disease mechanisms underlying SCA3.
Show less- All authors
- Toonen, L.J.A.
- Supervisor
- Dunnen, J.T. den
- Co-supervisor
- Roon-Mom, W.M.C. van
- Committee
- Aartsma-Rus, A.M.; Kampinga, H.H.; Warrenburg, B. van de
- Qualification
- Doctor (dr.)
- Awarding Institution
- Medicine, Leiden University Medical Center (LUMC) , Leiden University
- Date
- 2018-05-31
- ISBN (print)
- 9789461828835
Funding
- Sponsorship
- ADCA vereniging Nederland